RE:New Invivo Findings Press Release Sort1+ Solid news. A few points.
1. We knew there were other cancers over expressing SORT1 but they had not done the full in vivo tests to see if either of the PDCs worked. Now we know the taxal based one does in a bunch more. How well it does we will only know from the cancer forum presentation.
2. They've figured out the max dosage they can use balancing max effectiveness with negligible side effects and its large at 3x. Since they discuss this as a Pre-IND study it tells you they probably have done the last thing they needed to do prior to submitting the IND. they have the dosage, the target, the length, the preliminary safety data (not in humans), so they seem to be hinting they have what's needed so assume the IND is going in now or shortly.
3. A few weeks ago I posted that article about how SORT1 was also found in blood cancers and that could be something down the road AFTER this that they test. Looks like they read the same article no have already tested it in them as it's now on the list. They also mention you can combine the peptide with TKIs and those are anti cancer drugs many of which are used NAS like leukemia (and other cancers) and they work on the VEGAF gene. You'll recall I posted yesterday about how that was thought to be a way to amplify any immunotherapy drug since it was causing trouble with the immune cell response to fight the cancer. I was guessing they could somehow find a way to make every immunotherapy drug a lot better. So maybe they will still figure that out later given VEGAF seems to be part of their tool kit.
All in, the platform is now targeting more and seems they will hit the timeline of getting the IND end by year end and the Phase 1 up and going in 2021 (I think they say "early" now).